<DOC>
	<DOCNO>NCT01805908</DOCNO>
	<brief_summary>The general objective study improve care woman Human Epidermal Growth Factor Receptor-2 ( HER2 ) positive metastatic locally advanced breast cancer use radio-labelled biomarker whole body Single Photon Emission Computed Tomography ( SPECT ) image predict respond treatment Trastuzumab .</brief_summary>
	<brief_title>Imaging With 111 Indium ( 111In ) -Pertuzumab ( PmAb ) Predict Response Trastuzumab ( TmAb ) Human Epidermal Growth Factor-2 ( HER2 ) Positive Metastatic Breast Cancer ( MBC ) Locally Advanced Breast Cancer ( LABC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Metastatic , locally recurrent ( local recurrence amenable surgical resection curative intent ) , locally advanced ( T3 T4 , N , M0 ) adenocarcinoma breast . 2 . Tumour HER2 positive immunohistochemistry HER2 protein overexpression Fluorescence situ Hybridization ( FISH ) HER2 gene amplification , define American Society Clinical Oncology/College American Pathologists guideline 3 . Initiating treatment TmAb 4 . Clinically measurable disease ( RECIST patient metastatic disease ) . 1 . Male gender . 2 . Less 18 year age . 3 . Life expectancy &lt; 12 week . 4 . Only site metastasis liver . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . 6 . Currently receive PmAb lapatinib treatment MBC . 7 . Having receive TmAb adjuvant therapy within previous 6 month . 8 . Required receive another radiopharmaceutical first week study . 9 . Hypersensitivity monoclonal antibody . 10 . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % baseline ( within 42 day study registration ) determine either echocardiogram ( ECHO ) MultiGated Acquisition ( MUGA ) scan . 11 . Hematology and/or biochemistry parameter outside acceptable range : absolute neutrophil count &lt; 1,500 cells/mm3 , platelet count &lt; 100,000 cells/mm3 , hemoglobin &lt; 9 g/dL , total bilirubin &gt; upper limit normal ( ULN ) ( unless subject document Gilbert 's Syndrome ) , aspartate aminotransferase ( AST ) [ serum glutamic oxaloacetic transaminase ( SGOT ) ] alanine aminotransferase ( ALT ) [ serum glutamic pyruvate transaminase ( SGPT ) ] &gt; 2.5 × ULN , serum creatinine &gt; 2.0 mg/dL 177 μmol/L , alanine aminotransferase ( ALP ) &gt; 2.5 x ULN . 12 . Known pregnancy lactate female ( e.g . positive serum betahuman chorionic gonadotropin ( BhCG ) pregnancy test ) . 13 . For woman childbearing potential , failure agree use highly effective form contraception ( patient and/or partner , e.g. , surgical sterilization ) two effective form contraception ( reliable barrier method conjunction spermicidal jelly , birth control pill , contraceptive hormone implant ) continue use duration study treatment . 14 . Any condition , investigator 's opinion would make patient suitable candidate inclusion trial . 15 . Participation another clinical trial . 16 . Inability provide inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>breast cancer</keyword>
	<keyword>herceptin</keyword>
	<keyword>image</keyword>
	<keyword>tumour response</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>SPECT-CT</keyword>
	<keyword>pertuzumab</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>locally advanced</keyword>
</DOC>